focus -WSS

focus

author：Wikipedia 2025-09-06 02:15:13 - browse：9276

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： What’s missing from the debate over nursing home staff minimums

Wikipedia

WSS

First over

Readout Newsletter: BridgeBio, Akero, and human embryo models

For AI in health care standards, federal regulators join with industry group

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Biden's 'march

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

focus

focus

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Gene therapy for Afghan refugees’ infant will be fully covered

After affirmative action ruling, medical educators look to 'holistic review'

Why Novartis is going to walk from its acquisition of MorphoSys

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: BridgeBio, Akero, and human embryo models

Trump demands the U.S. pay no more for drugs than other countries … again

Texas Medical Board asked to define abortion emergency exception

Duchenne breakthrough therapy leaves behind pioneering families

Change Healthcare: What is it, why does its cyberattack matter?

focus

Streamlined flu vaccines recommended by FDA advisory panel

Readout LOUD: Venture capital, Gilead, and more M&A

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Florida health officials providing scant details on measles cases

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Immune cells and nerve overgrowth may explain recurring UTI pain

hotspot

Wikipedia

explore

leisure time